Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma

[1]  L. Wilkins.  CD3 Antibody and IL‐2 Complex Combination Therapy Inhibits Atherosclerosis by Augmenting a Regulatory Immune Response , 2015, Journal of the American Heart Association.

[2]  G. Malaguarnera,et al.  Hepatocellular Carcinoma: Novel Molecular Targets in Carcinogenesis for Future Therapies , 2014, BioMed research international.

[3]  C. Contag,et al.  A killer choice for cancer immunotherapy , 2014, Immunologic Research.

[4]  Huiping Wang,et al.  Dendritic Cells Decreased the Concomitant Expanded Tregs and Tregs Related IL-35 in Cytokine-Induced Killer Cells and Increased Their Cytotoxicity against Leukemia Cells , 2014, PloS one.

[5]  T. Fehniger,et al.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  Huiping Wang,et al.  Targeting regulatory T cells in cytokine-induced killer cell cultures (Review) , 2014, Biomedical reports.

[7]  X. Hao,et al.  Maintenance Therapy With Autologous Cytokine-induced Killer Cells in Patients With Advanced Epithelial Ovarian Cancer After First-line Treatment , 2014, Journal of immunotherapy.

[8]  J. Marrero,et al.  Emerging Trends in Hepatocellular Carcinoma: Focus on Diagnosis and Therapeutics , 2014, Clinical Medicine Insights. Oncology.

[9]  S. Hongeng,et al.  Sunitinib Indirectly Enhanced Anti-Tumor Cytotoxicity of Cytokine-Induced Killer Cells and CD3+CD56+ Subset through the Co-Culturing Dendritic Cells , 2013, PloS one.

[10]  Mingfeng Zhao,et al.  Multiple cytotoxic factors involved in IL-21 enhanced antitumor function of CIK cells signaled through STAT-3 and STAT5b pathways. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[11]  G. Malaguarnera,et al.  Systemic therapies in hepatocellular carcinoma: present and future. , 2013, Future oncology.

[12]  M. Heikenwalder,et al.  Adoptive T-cell therapy to treat liver cancer: Is the liver microenvironment key? , 2013, Oncotarget.

[13]  Ke-Cheng Xu,et al.  Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma. , 2013, World journal of gastroenterology.

[14]  J. Ritz,et al.  Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease , 2013, Science Translational Medicine.

[15]  Linping Xu,et al.  Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature , 2013, Oncology letters.

[16]  Y. Zeng,et al.  The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer , 2013, Tumor Biology.

[17]  Jingting Jiang,et al.  Cytokine-induced killer cells promote antitumor immunity , 2013, Journal of Translational Medicine.

[18]  E. Shevach.  Application of IL-2 therapy to target T regulatory cell function. , 2012, Trends in immunology.

[19]  E. Bonifacio,et al.  IL-7 Abrogates Suppressive Activity of Human CD4+CD25+FOXP3+ Regulatory T Cells and Allows Expansion of Alloreactive and Autoreactive T Cells , 2012, The Journal of Immunology.

[20]  Xin-ji Zhang,et al.  Adoptive Immunotherapy in Postoperative Hepatocellular Carcinoma: A Systemic Review , 2012, PloS one.

[21]  W. Piacibello,et al.  Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors , 2012, Expert opinion on biological therapy.

[22]  X. Hao,et al.  Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study , 2012, Cancer Immunology, Immunotherapy.

[23]  Yi-jun Wang,et al.  Foxp3+ regulatory T cells are associated with the natural history of chronic hepatitis B and poor prognosis of hepatocellular carcinoma , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[24]  Jun Wu,et al.  Review of Chinese clinical trials on CIK cell treatment for malignancies , 2012, Clinical and Translational Oncology.

[25]  J. Yeh,et al.  Inhibition of peripheral blood natural killer cell cytotoxicity in patients with myasthenia gravis treated with plasmapheresis , 2011, European journal of neurology.

[26]  B. Han,et al.  Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer , 2011, Cancer Immunology, Immunotherapy.

[27]  D. Sangiolo.  Journal of Cancer Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors , 2022 .

[28]  P. Liang,et al.  Phase Ⅰ clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma , 2011, Cancer biology & therapy.

[29]  Hongwei Wang,et al.  Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells , 2010, International journal of hematology.

[30]  K. Pan,et al.  Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. , 2010, Chinese journal of cancer.

[31]  Jennifer A. Prescher,et al.  IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy , 2010, Cancer Immunology, Immunotherapy.

[32]  Hui Li,et al.  CD4+CD25+ Regulatory T Cells Decreased the Antitumor Activity of Cytokine-Induced Killer (CIK) Cells of Lung Cancer Patients , 2007, Journal of Clinical Immunology.

[33]  M. Yamaguchi,et al.  Cytotoxic difference of T cells expanded with anti-CD3 monoclonal antibody in the presence and absence of anti-CD 28 monoclonal antibody. , 2004, Stem cells and development.

[34]  Bingzhang,et al.  Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma , 2004 .

[35]  S. Steinberg,et al.  Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Pakakasama,et al.  Generation of CD3+CD56+ Cytokine-Induced Killer Cells and Their In Vitro Cytotoxicity against Pediatric Cancer Cells , 2003, International journal of hematology.